Qube Research & Technologies LTD Akero Therapeutics, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $82.3 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$406 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$387 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$325 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$306 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$287 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.54B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...